Lauri E. Markowitz (United States of America)

Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases

Presenter of 2 Presentations

 Conference Calendar
Public Health / Epidemiology / Vaccination: Implementation, Evaluation and Impact ePoster

THE USA HPV VACCINATION PROGRAM: POLICY, IMPLEMENTATION AND IMPACT (ID 1153)

Session Date
07/21/2020
Session Time
10:00 - 17:00
Room
ePoster
Session Type
Poster Viewing - 20-24 July
Session Name
Public Health / Epidemiology / Vaccination: Implementation, Evaluation and Impact
Lecture Time
10:33 - 10:34
Presenter
Authors

Abstract

Introduction

Human papillomavirus (HPV) vaccine was introduced into the national USA immunization program in 2006; vaccination policy has evolved as additional HPV vaccines were licensed and new data became available. Vaccination coverage is increasing although consistently lower than for other adolescent vaccinations. Routine safety monitoring and projects for impact evaluation are being conducted.

Methods

We reviewed recommendations from the Advisory Committee on Immunization Practices, vaccination coverage data from the annual National Immunization Survey-Teen, and reports from several safety and vacccine impact monitoring systems, including the National Health and Nutrition Examination Survey.

Results

Routine HPV vaccination was recommended at age 11-12 years in 2006 for females and in 2011 for males, with catch-up through age 26 for females and age 21 for males. Catch-up recommendations were harmonized through age 26 in 2019. Most vaccine used through 2014 was quadrivalent vaccine (4vHPV). 9-valent vaccine (9vHPV), introduced in 2015, was the only vaccine available after 2016. At least 1-dose and up-to-date coverage among 13-17 year-olds in 2018 was 70% and 54% among girls; 66% and 49% among boys. Vaccination coverage has been increasing; between 2017 and 2018 coverage increased only among boys. There are various reasons for low coverage; efforts are ongoing to increase vaccine uptake. Through June 2019, about 43 million 9vHPV doses were distributed in the United States; 9vHPV safety profile is similar to 4vHPV. 4vHPV-type HPV prevalence in self-collected cervicovaginal swabs declined 86% between the prevaccine era and 2013-2016 among 14-19 year-olds and 71% among 20-24 year-olds. Declines also have been observed in anogenital warts and cervical precancers.

Conclusions

The United States was the first country to introduce HPV vaccine and currently has a gender-neutral vaccination program. The vaccine safety profile has been well established by 12 years of monitoring. Given moderate vaccination coverage, impact on HPV prevalence and HPV-associated outcomes has exceeded expectations.

Hide
Oral Session 12: EPIDEMIOLOGY I. Natural history and risk factors  Hall F

EXPLORATION OF INDIVIDUAL HUMAN PAPILLOMAVIRUS (HPV) TYPES AND TYPE REPLACMENT AFTER VACCINE INTRODUCTION, OVERALL AND BY RACE, UNITED STATES (ID 606)

Session Date
07/23/2020
Session Time
08:30 - 09:55
Room
Hall F
Session Type
Public Health Oral Session
Session Name
Oral Session 12: EPIDEMIOLOGY I. Natural history and risk factors 
Lecture Time
09:06 - 09:18
Presenter
Authors

Moderator of 1 Session

 Conference Calendar
Public Health Oral Session

00990 - Oral Session 15: VACCINATION V. Impact and effectiveness (ID 54)

Session Type
Public Health Oral Session
Session Date
07/24/2020
Session Time
09:00 - 10:00
Room
Hall D
Chair(s)

Session Webcast